Abstract 130P
Background
Neoadjuvant treatment of immune checkpoint inhibitors have shown a high pathologic complete response (pCR) rate in patients with dMMR/MSI-H, locally advanced colorectal cancer (LACRC). Cadonilimab (AK104), a novel bispecific antibody simultaneously targeting PD-1 and CTLA-4, was designed to boost anti-tumor activity with a favorable safety profile. Here, we primary reported the efficacy and safety of AK104 in the neoadjuvant treatment of dMMR/MSI-H LACRC, while concurrently exploring the potential for surgery avoidance.
Methods
The study was a multi-cohort, phase 2 trial, consisted of Cohort A (locally advanced colon cancer) and B (Locally Advanced Rectal Cancer). Patients (pts) with dMMR/MSI-H, LACRC were enrolled to receive AK104 (10mg/kg, iv, d1, q3w) for up to 8 cycles. The primary endpoint is the complete response rate (CR, pCR plus cCR). Secondary endpoints include MPR rate, R0 resection rate, DFS, OS, and safety.
Results
From April 2023 to August 2024, 34 pts were enrolled (26 in Cohort A and 8 in Cohort B). Baseline characteristics of pts are listed in the table. 34 pts had at least 2 cycles of treatment. In Cohort B, 4 pts completed the entire neoadjuvant treatment, and all reached the cCR. Currently, 13 pts (12 in Cohort A and 1 in Cohort B) received surgical resection, and the R0 resection rate was 100%. The pCR rate was 84.6% (11/13) and the MPR rate was 100 % (13/13). The median DFS was not reached. Treatment-related adverse events (TRAEs) occurred in 18/34(53%) pts. 5 /34 (14.7%) pts experienced grade 3-4 treatment-related adverse events (TRAEs), which included adrenocortical hypofunction (1 pt), myocarditis (1 pt), myositis (2 pts), and thrombocytopenia (1pt). No grade 5 AEs were observed. Table: 130P
Characteristics | Cohort A, N=26 | Cohort B, N=8 |
Age (years, median range) | 52 (18, 73) | 55 (48,68) |
Gender | ||
Female | 11 (42) | 1 (13) |
Male | 15 (58) | 7 (87) |
ECOG PS | ||
0 | 18 (69) | 6 (75) |
1 | 8 (31) | 2 (25) |
Clinical T category | ||
cT3 | 6 (23) | 5 (62) |
cT4a | 20 (77) | 3 (38) |
Clinical N category | ||
N+ | 26 (100) | 7 (88) |
N0 | 0 (0) | 1 (12) |
Conclusions
Cadonilimab showed promising efficacy with an outstanding pCR rate and manageable safety profile in locally advanced dMMR/MSI-H colorectal cancer patients. This trial is still ongoing and needs long-term follow-up.
Clinical trial identification
NCT05815290.
Legal entity responsible for the study
The authors.
Funding
Akeso Biopharma.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
216P - Spatial transcriptomics reveals tumor-microenvironment heterogeneity of breast cancer
Presenter: Hyun Lee
Session: Poster Display session
Resources:
Abstract
217P - Tumor-derived CCL15 regulates RNA m6A methylation in cancer-associated fibroblasts to promote hepatocellular carcinoma growth
Presenter: Yueguo Li
Session: Poster Display session
Resources:
Abstract
218P - A novel tumor adenosine signature to guide indication selection for adenosine pathway inhibitors
Presenter: Sophie Dekoninck
Session: Poster Display session
Resources:
Abstract
219P - Radiotherapy, in conjunction with a PI3Kd/? inhibitor, enhances effector CD8+ T cell-mediated anti-tumor immune responses and the memory function of T cells within the tumor microenvironment by stimulating innate immunity
Presenter: Ye hyun Kim
Session: Poster Display session
Resources:
Abstract
220P - Correlation research between oral flora diversity and radiation-induced stomatitis after postoperative radiotherapy for oral squamous cell carcinoma
Presenter: Qin Zheng
Session: Poster Display session
Resources:
Abstract
221P - Chemoradiotherapy induced adaptive anti-tumor T cell immunity in patients with non-small cell lung cancer
Presenter: Yaoyao Xie
Session: Poster Display session
Resources:
Abstract
222P - Features of epithelial-to-mesenchymal transition (EMT) and humoral immune response in ulcerated acral melanoma: A transcriptomic and spatial proteomic analysis.
Presenter: Estefania Vazquez
Session: Poster Display session
Resources:
Abstract
223P - Frequency of the number of myeloid-derived suppressor cells in patients with lung cancer according to T stage
Presenter: Jelena Vukovic
Session: Poster Display session
Resources:
Abstract
224P - Immunological Dynamics in Triple-Negative Breast Cancer: Peripheral Immune Responses to Neoadjuvant Therapy
Presenter: Rita Santos
Session: Poster Display session
Resources:
Abstract
225P - Assessment of immune cell populations in the peripheral blood of metastatic prostate cancer
Presenter: Vanessa Patel
Session: Poster Display session
Resources:
Abstract